WeightControl.com Interview with:
Xiaoying Li, MD
Professor and Director
Ying Chen, MD
Associate Professor
Department of Endocrinology and Metabolism
Zhongshan Hospital, Fudan University
Shanghai 200032 China
WeightControl.com: What is the background for this study?
Response: Overweight and obesity affect more than 50% of the population in China. In the SUROMOUNT-CN study, we have reported that the GIP/GLP-1 RA, tirzepatide led to a substantial weight loss of 14.4% and 19.9% by 10 mg and 15 mg treatment for 52 weeks, respectively, in overweight or obese Chinese adults. This observational study further evaluated weight loss maintenance following tirzepatide discontinuation.